The U.S. Food and Drug Administration (FDA) approved Phathom Pharmaceuticals’ vonoprazan (Voquenza) on November 1, 2023 for the treatment of adults with erosive esophagitis (erosive GERD), a gastroesophageal reflux disease. The drug is expected to be commercially available by December 2023. The drug’s approval marks a critical moment for more than 20 million patients suffering …
For those suffering from stubbornly resistant forms of severe depression, ketamine is increasingly emerging as a solution. Years of research have hinted at the therapeutic potential of the dissociative anesthetic where other drugs have failed, promising the benefits of electroconvulsive therapy with far fewer risks. Despite all the enthusiasm, separating hope from hype has been …
Rates of depression and anxiety, high even before COVID-19, have increased in recent years thanks to the pandemic. The World Health Organization estimates that these diseases affect a quarter of the world’s population and cost the global economy $1 trillion per year. Treatment includes talk therapy, but much can be done within the confines of …
Pilocarpine hydrochloride ophthalmic solution 0.4% (Qlosi, Orasis Pharmaceuticals) has received FDA approval for the treatment of presbyopia in adults. Presbyopia is the loss of the ability to focus on nearby objects and is caused by the natural aging process. A press release from Orasis states that 128 million people in the United States are affected …
The number of Arkansans covered by Medicaid or private insurance who filled a prescription for naloxone increased 340% following the passage of a law requiring an anti-overdose medication to be prescribed to patients receiving high doses of naloxone. opioids, according to an analysis by the Arkansas Center. for the improvement of health. According to the …